26th April 2021 Product update: rapidmicrobiology staff writer
Point-of-Care PCR Test for COVID-19 is Awarded NIH Contract
Minute Molecular Diagnostics, Inc., (Minute Molecular) has been awarded a $21.3 million contract from the U.S. National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative for the company’s DASH (Diagnostic Analyzer for Specific Hybridization) point-of-care PCR system for COVID-19 testing.
The contract supports further development of Minute Molecular’s DASH SARS-CoV-2 test, which allows highly sensitive PCR testing to take place at the point-of-care, and outside the traditional laboratory environment.
“We are pleased to receive support from NIH through the RADx initiative to scale our innovative technology during this critical time of need,” said Dr. David Kelso, co-founder, President, and CEO of Minute Molecular Diagnostics. “DASH performs point-of-care PCR testing for COVID-19 in approximately 15 minutes, providing an important, new tool for safely re-opening K-12 schools, universities, and workplaces.”
“DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes,” said Dr. Sally McFall, co-founder and Chief Scientific Officer at Minute Molecular. “The simplicity of the DASH test allows PCR testing to go where antigen tests go now.”
The DASH system is the result of collaboration between Northwestern University’s Center for Innovation in Global Health Technologies (CIGHT) and Minute Molecular. The RADx Tech contract will enable the development and manufacturing scale-up of a highly sensitive COVID-19 detection system.
Date Published: 26th April 2021
Source article link: View
Note: This content has been edited by a rapidvirology.com staff writer for style and content.
CovClear™ COVID-19 Rapid Antigen
Ultragene SARS-CoV-2 Variant Triplex Assay